Axsome Therapeutics
221 articles about Axsome Therapeutics
-
Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference
2/7/2023
Axsome Therapeutics, Inc. today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, Feb. 15, 2023, at 8:40 a.m. Eastern Time.
-
Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27Axsome to host conference call and webcast on Monday, Feb. 27, 2023, at 8:00 a.m. ET
1/31/2023
Axsome Therapeutics, Inc. today announced that it will report its financial results for the fourth quarter and full year of 2022 on Monday, Feb. 27, 2023, before the opening of the U.S. financial markets.
-
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder
12/7/2022
Axsome Therapeutics, Inc. today announced that treatment with AUVELITY® (dextromethorphan HBr-bupropion HCl) resulted in rapid, substantial, and durable improvements in cognitive and physical functioning in the EVOLVE open-label trial in major depressive disorder (MDD).
-
A Phase III trial of Axsome Therapeutics’ AXS-05 hit both the primary and secondary endpoints in patients with Alzheimer’s disease agitation, the New York-based company announced Monday.
-
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
11/28/2022
Axsome Therapeutics, Inc. today announced that AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary and key secondary endpoints in the ACCORD (Assessing Clinical Outcomes in Alzheimer’s Disease Agitation) Phase 3 trial.
-
Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
11/23/2022
Axsome Therapeutics, Inc. today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Wednesday, November 30, 2022 at 12:10 PM Eastern Time.
-
Axsome Therapeutics to Present at the Guggenheim 4th Annual Immunology and Neurology Conference
11/9/2022
Axsome Therapeutics, Inc. today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Conference on Tuesday, November 15, 2022 at 10:45 AM Eastern Time.
-
Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
11/7/2022
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2022.
-
Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022
10/21/2022
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter of 2022 on Monday, November 7, 2022 before the opening of the U.S. financial markets.
-
Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
10/20/2022
Axsome Therapeutics, Inc. today announced that AUVELITY™ (dextromethorphan HBr-bupropion HCl) is now available by prescription in the United States for the treatment of major depressive disorder (MDD) in adults.
-
Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022
10/10/2022
Axsome Therapeutics, Inc. is joining the World Health Organization’s (WHO) 2022 World Mental Health Day campaign to make mental health and well-being for all a global priority.
-
Axsome Therapeutics Announces Sunosi® (Solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cognitive Function in the SHARP Trial
10/3/2022
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced that Sunosi met the primary endpoint in the SHARP study and significantly improved cognitive function, measured using the Digit Symbol Substitution Test.
-
Axsome Therapeutics Announces Plans to Resubmit AXS-07 NDA Based on Successful FDA Type A Meeting
9/29/2022
Axsome Therapeutics, Inc. announced that, following a Type A meeting with the U.S. Food and Drug Administration (FDA), it intends to resubmit its New Drug Application (NDA) for AXS-07 for the acute treatment of migraine in the third quarter of 2023.
-
Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation
9/8/2022
Axsome Therapeutics, Inc. announced that it has enrolled the first patient in the ADVANCE-2 trial of AXS-05, an investigational treatment for Alzheimer’s disease agitation.
-
In the second half of the calendar year, the biopharma industry continues to ascend in mergers and acquisitions, new drug approvals and big investments, indicate market confidence and growth.
-
The FDA is busy accepting drug applications, granting specialty designations and approving drugs for market. Here's a look at this week's FDA activity.
-
The FDA's decision on Axsome Therapeutics' Auvelity is based on positive results from a massive clinical program that covered over 1,100 patients with depression.
-
Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
8/19/2022
Axsome Therapeutics, Inc. announced that the FDA has approved AUVELITY™ extended-release tablets for the treatment of major depressive disorder in adults.
-
Axsome Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
7/28/2022
Axsome Therapeutics, Inc. today announced that it will report its financial results for the second quarter of 2022 on Tuesday, August 9, 2022 before the opening of the U.S. financial markets.
-
Axsome hosted an investor day event to provide an update on plans for Sunosi and other developmental assets, including MDD treatment AXS-05.